Analysts' Top 5 Price Targets of August 7, 2025
Reading Time: 4 minutes
Liquidia Technologies [US53635D2027] LifeSci Capital confirms Buy rating with a price target of $41 (100% upside potential) The early approval of the drug Yutrepia by the FDA on May 23, 2025, and the rapid commercial launch just a few days later demonstrate remarkable execution by the company. By early June, Yutrepia was delivered through specialty pharmacies, included in drug listings, and actively promoted by the sales team. This speed underscores Liquidia 's strategic focus on establishing Yutrepia as the preferred prostacyclin...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
